Literature DB >> 29957236

The Role of Nutraceuticals in Statin Intolerant Patients.

Maciej Banach1, Angelo Maria Patti2, Rosaria Vincenza Giglio2, Arrigo F G Cicero3, Atanas G Atanasov4, Gani Bajraktari5, Eric Bruckert6, Olivier Descamps7, Dragan M Djuric8, Marat Ezhov9, Zlatko Fras10, Stephan von Haehling11, Niki Katsiki12, Michel Langlois13, Gustavs Latkovskis14, G B John Mancini15, Dimitri P Mikhailidis16, Olena Mitchenko17, Patrick M Moriarty18, Paul Muntner19, Dragana Nikolic2, Demosthenes B Panagiotakos20, Gyorgy Paragh21, Bernhard Paulweber22, Daniel Pella23, Christos Pitsavos24, Željko Reiner25, Giuseppe M C Rosano26, Robert S Rosenson27, Jacek Rysz28, Amirhossein Sahebkar29, Maria-Corina Serban30, Dragos Vinereanu31, Michal Vrablík32, Gerald F Watts33, Nathan D Wong34, Manfredi Rizzo2.   

Abstract

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non-lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular risk; dyslipidemia; nutraceuticals; position paper; statin intolerance

Mesh:

Substances:

Year:  2018        PMID: 29957236     DOI: 10.1016/j.jacc.2018.04.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  47 in total

Review 1.  Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management.

Authors:  Amanda Bergamin; Evangeline Mantzioris; Giordana Cross; Permal Deo; Sanjay Garg; Alison M Hill
Journal:  Pharmaceut Med       Date:  2019-08

Review 2.  Red Yeast Rice for Hypercholesterolemia.

Authors:  Arrigo F G Cicero; Federica Fogacci; Maciej Banach
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Jul-Sep

3.  AGR2-induced cholesterol synthesis drives lovastatin resistance that is overcome by combination therapy with allicin.

Authors:  Nan Sheng; Yun-Qiu Wang; Cun-Fu Wang; Meng-Qi Jia; Huan-Min Niu; Qi-Qi Lu; Ya-Nan Wang; Dan Feng; Xiao-Xue Zheng; Hui-Qing Yuan
Journal:  Acta Pharmacol Sin       Date:  2022-04-22       Impact factor: 6.150

4.  The Effect of Green Coffee Bean Extract on Cardiovascular Risk Factors: A Systematic Review and Meta-analysis.

Authors:  Makan Pourmasoumi; Amir Hadi; Wolfgang Marx; Ameneh Najafgholizadeh; Sukhdeep Kaur; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

Review 6.  Statin-Associated Muscle Disease: Advances in Diagnosis and Management.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

7.  Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation.

Authors:  Arrigo F G Cicero; Federica Fogacci; Marilisa Bove; Fulvio Ventura; Marina Giovannini; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-09-18

Review 8.  The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair.

Authors:  Parinaz Zivarpour; Željko Reiner; Jamal Hallajzadeh; Liaosadat Mirsafaei; Zatollah Asemi
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

9.  The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.

Authors:  I Marková; H Malínská; M Hüttl; D Miklánková; O Oliyarnyk; M Poruba; Z Rácová; L Kazdová; R Večeřa
Journal:  Physiol Res       Date:  2021-01-14       Impact factor: 1.881

10.  Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study.

Authors:  Stefania Raimondo; Dragana Nikolic; Alice Conigliaro; Gianluca Giavaresi; Bruna Lo Sasso; Rosaria Vincenza Giglio; Roberta Chianetta; Mauro Manno; Samuele Raccosta; Valeria Corleone; Giovanni Ferrante; Roberto Citarrella; Manfredi Rizzo; Giacomo De Leo; Marcello Ciaccio; Giuseppe Montalto; Riccardo Alessandro
Journal:  Metabolites       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.